SCHEMBL2381980

SCHEMBL2381980

O=C(O)CCCCCCCCCCc1cc(O)ccc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F13A1 P00488 3/20 0.59
EGFR P00533 2/20 0.51
LCK P06239 1/20 0.51
MAPT P10636 2/20 0.50
RXFP1 Q9HBX9 1/20 0.50
LTB4R Q15722 3/20 0.48
TP53 P04637 2/20 0.46
CYP3A4 P08684 2/20 0.46
ALOX15 P16050 2/20 0.46
TSHR P16473 2/20 0.46
MEN1 O00255 1/20 0.46
ALOX5 P09917 1/20 0.46
TYR P14679 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4148828 1.00 F13A1 (0.59) F13A1EGFRLCKMAPTRXFP1
SCHEMBL3840098 1.00 F13A1 (0.59) F13A1EGFRLCKMAPTRXFP1
SCHEMBL3838231 1.00 F13A1 (0.59) F13A1EGFRLCKMAPTRXFP1
SCHEMBL6582394 0.98 F13A1 (0.56) F13A1EGFRLCKMAPTRXFP1
SCHEMBL3842422 0.93 EGFR (0.54) F13A1EGFRLCKTP53CYP3A4
SCHEMBL3835233 0.90 F13A1 (0.49) F13A1EGFRLCKMAPTRXFP1
SCHEMBL13065628 0.87 TYR (0.57) EGFRLCKMAPTTP53CYP3A4
SCHEMBL10602853 0.86 TP53 (0.47) F13A1EGFRLCKMAPTTP53
SCHEMBL7785687 0.86 EGFR (0.47) F13A1EGFRLCKMAPTTP53
SCHEMBL8764494 0.86 TYR (0.59) F13A1MAPTTP53CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5449518-A Bleaching, decoloring skin L'OREAL (FR) 1995-09-12 US claimed
EP-0526302-B1 Depigmentation composition containing derivatives of (2,5-dihydroxyphenyl)-carboxylica OREAL (FR) 1995-03-01 EP claimed
US-8505730-B2 Compositions, kits and regimens for the treatment of skin, especially décolletage JR CHEM, LLC (US) 2013-08-13 US disclosed
US-8466311-B2 Neuroprotective compositions and methods SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2013-06-18 US disclosed
US-8466311-B2 Neuroprotective compositions and methods SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2013-06-18 US disclosed
US-20120312717-A1 COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE JR CHEM, LLC (US) 2012-12-13 US disclosed
US-20120296112-A1 Neuroprotective Compositions and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-11-22 US disclosed
US-20120296112-A1 Neuroprotective Compositions and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-11-22 US disclosed
US-8273791-B2 Compositions, kits and regimens for the treatment of skin, especially décolletage JR CHEM, LLC (US) 2012-09-25 US disclosed
US-8022246-B2 Neuroprotective compositions and methods THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2011-09-20 US disclosed
US-8022246-B2 Neuroprotective compositions and methods THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2011-09-20 US disclosed
US-20010036446-A1 Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives L'OREAL (FR) 2001-11-01 US disclosed
US-5667792-A CARBOXY DERIVATIVES OF HYDROQUINONE AS BLEACHES FOR SKIN L'OREAL (FR) 1997-09-16 US disclosed
US-5637756-A TREATMENT OF SKIN DISORDERS, BLEACHING OF PIGMENTED SPOTS, COSMETICS L'OREAL (FR) 1997-06-10 US disclosed
US-5587173-A Utilization of derivatives of 2,5 dihydroxyphenyl-carboxylic acid amides and their salts in preparation of a cosmetic or dermatological composition with a depigmenting action L'OREAL (FR) 1996-12-24 US disclosed
US-5585105-A Utilization of derivatives of 2,5-dihydroxyphenylcarboxylic acids, their homologs, and their salts in preparation of a cosmetic or dermatological composition with a depigmenting action L'OREAL (FR) 1996-12-17 US disclosed
US-5449518-A Bleaching, decoloring skin L'OREAL (FR) 1995-09-12 US disclosed
US-5190689-A Polymer materials having liquid-crystalline phases MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1993-03-02 US disclosed
EP-0220463-B1 POLYMER MATERIALS PRESENTING A LIQUID CRYSTAL PHASE MERCK PATENT GmbH (DE) 1992-01-02 EP disclosed
EP-0220463-A2 Polymer materials presenting a liquid crystal phase MERCK PATENT GmbH (DE) 1987-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120296112-A1 Neuroprotective Compositions and Methods KEAP1, NFE2L2, NQO1 F13A1 4703/4885EGFR 3947/4885LCK 4783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.